HIV vaccine design and the neutralizing antibody problem

Nature Immunology

Volumn 5, Issue 3, 2004, Pages 233-236

  Burton, Dennis R ^a   Desrosiers, Ronald C ^b   Doms, Robert W ^c   Koff, Wayne C ^d   Kwong, Peter D ^e   Moore, John P ^f   Nabel, Gary J ^e   Sodroski, Joseph ^b   Wilson, Ian A ^a   Wyatt, Richard T ^e  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G ANTIBODY; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2F5; NEUTRALIZING ANTIBODY; RANTES; VIRUS ENVELOPE PROTEIN; EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIGEN BINDING; BINDING SITE; CLINICAL TRIAL; CROSS REACTION; DRUG DESIGN; DRUG EFFICACY; DRUG INDUSTRY; DRUG TARGETING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; NONHUMAN; NOTE; PRIORITY JOURNAL; VACCINATION; VIRUS CELL INTERACTION; VIRUS ISOLATION; ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; IMMUNOLOGY; SERODIAGNOSIS;

AIDS VACCINES; ANTIBODIES, MONOCLONAL; DRUG DESIGN; EPITOPES; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; MODELS, MOLECULAR; NEUTRALIZATION TESTS;

EID: 1542317452     PISSN: 15292908     EISSN: None     Source Type: Journal    
DOI: 10.1038/ni0304-233     Document Type: Note

References (21)

1. Wyatt, R. & Sodroski, J. Science 280, 1884-1888 (1998).
2. Parren, P.W. & Burton, D.R. Adv. Immunol. 77, 195-262 (2001).
3. Johnson, W.E. & Desrosiers, R.C. Annu. Rev. Med. 53, 499-518 (2002).
4. Saphire, E.O. et al. Science 293, 1155-1159 (2001).
5. Calarese, D.A. et al. Science 300, 2065-2071 (2003).
6. Zwick, M. B. et al. J. Virol. 75, 10892-10905 (2001).
7. Stanfield, R.L., Gorny, M.K., Williams, C., Zolla-Pazner, S. & Wilson, I.A. Structure (in the press).
8. Sharon, M. et al. Structure (Camb) 11, 225-236 (2003).
9. Proudfoot, A.E. et al. J. Biol. Chem. 276, 10620-10626 (2001).
10. Labrijn, A.F. et al. J. Virol. 77, 10557-10565 (2003).
11. Choe, H. et al. Cell 114, 161-170 (2003).
12. Golding, H. et al. J. Virol. 76, 6780-6790 (2002).
13. Sanders, R.W. et al. J. Virol. 76, 8875-8889 (2002).
14. Yang, X., Wyatt, R. & Sodroski, J. J. Virol. 75, 1165-1171 (2001).
15. Grundner, C., Mirzabekov, T., Sodroski, J. & Wyatt, R. J. Virol. 76, 3511-3521 (2002).
16. Srivastava, I.K. et al. J. Virol. 77, 11244-11259 (2003).
17. Pantophlet, R., Wilson, I.A. & Burton, D.R. J. Virol. 77, 5889-5901 (2003).
18. Fouts, T. et al. Proc. Natl. Acad. Sci. USA 99, 11842-11847 (2002).
19. Klausner, R.D. et al. Science 300, 2036-2039 (2003).
20. Kwong, P.D., Wyatt, R., Sattentau, Q.J., Sodroski, J. & Hendrickson, W.A. J. Virol. 74, 1961-1972 (2000).
21. Selvarajah, S. & Burton, D.R. Accelerating AIDS Vaccine Development. Challenges and Opportunities (eds. Kahn, P., Gust, P. & Koff, W.) (Horizon Scientific Press, Norwich, UK, in the press).